Key clinical point: Adding aggressive local radiotherapy to tyrosine kinase inhibitor (TKI) treatment improved progression-free and overall survival in patients with previously untreated, EGFR-mutated, oligometastatic non–small cell lung cancer.

Major finding: The median progression-free survival was 20.2 months in the radiotherapy arm and 12.5 months in the TKI-only arm (hazard ratio, 0.618; P < .001); the median overall survival was 25.5 months and 17.4 months, respectively (HR, 0.682; P < .001).

Study details: A phase 3 trial of 133 patients randomized to a first-generation TKI alone or to a TKI plus stereotactic body radiation therapy.

Disclosures: The study was sponsored by Sichuan Provincial People’s Hospital. The investigators had no relevant disclosures.